- Home
- ETON vs RMR Comparison
ETON vs RMR Comparison
Compare ETON & RMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | RMR |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 253.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ETON | RMR |
|---|---|---|
| Price | $15.96 | $15.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | ★ 282.6K | 189.0K |
| Earning Date | 11-06-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $70,316,000.00 | ★ $196,824,000.00 |
| Revenue This Year | $113.27 | $301.43 |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | ★ N/A | $15.13 |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $13.48 |
| 52 Week High | $23.00 | $21.96 |
Technical Indicators
Market Signals| Indicator | ETON | RMR |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 47.21 |
| Support Level | $15.75 | $14.85 |
| Resistance Level | $17.19 | $15.97 |
| Average True Range (ATR) | 0.73 | 0.33 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 35.08 | 39.46 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About RMR The RMR Group Inc.
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.